Acrivon Therapeutics Unveils Clinical Data and Pipeline Updates for ACR-368 and ACR-2316

Reuters

Jan 09

Acrivon <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Unveils Clinical Data and Pipeline Updates for ACR-368 and ACR-2316

Acrivon Therapeutics Inc. recently held a conference call to discuss clinical data and pipeline updates for its leading drug candidates, ACR-368 and ACR-2316. The presentation included initial Phase 1 clinical data for ACR-2316 and Phase 2b data for ACR-368, with updates on program progress and the nomination of a development candidate for the company’s cell cycle program. ACR-368, evaluated as a single agent in endometrial cancer subjects identified as OncoSignature-positive, demonstrated an objective response rate $(ORR)$ of 39% in the analyzed cohort. The company's AI-driven AP3 platform, designed to match disease-driving pathways with drug mechanisms, was also highlighted as a key component of its approach to precision medicine. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acrivon Therapeutics Inc. published the original content used to generate this news brief on January 08, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2602326275"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602326275\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602326275?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-09 17:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602326275","market":"fut","top_or_hot":-1,"title":"Acrivon Therapeutics Unveils Clinical Data and Pipeline Updates for ACR-368 and ACR-2316","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Acrivon <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils Clinical Data and Pipeline Updates for ACR-368 and ACR-2316\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Acrivon Therapeutics Inc. recently held a conference call to discuss clinical data and pipeline updates for its leading drug candidates, ACR-368 and ACR-2316. The presentation included initial Phase 1 clinical data for ACR-2316 and Phase 2b data for ACR-368, with updates on program progress and the nomination of a development candidate for the company’s cell cycle program. ACR-368, evaluated as a single agent in endometrial cancer subjects identified as OncoSignature-positive, demonstrated an objective response rate <a href=\"https://laohu8.com/S/ORR\">$(ORR)$</a> of 39% in the analyzed cohort. The company's AI-driven AP3 platform, designed to match disease-driving pathways with drug mechanisms, was also highlighted as a key component of its approach to precision medicine. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acrivon Therapeutics Inc. published the original content used to generate this news brief on January 08, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Acrivon Therapeutics Unveils Clinical Data and Pipeline Updates for ACR-368 and ACR-2316</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAcrivon Therapeutics Unveils Clinical Data and Pipeline Updates for ACR-368 and ACR-2316\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-09 17:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Acrivon <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils Clinical Data and Pipeline Updates for ACR-368 and ACR-2316\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Acrivon Therapeutics Inc. recently held a conference call to discuss clinical data and pipeline updates for its leading drug candidates, ACR-368 and ACR-2316. The presentation included initial Phase 1 clinical data for ACR-2316 and Phase 2b data for ACR-368, with updates on program progress and the nomination of a development candidate for the company’s cell cycle program. ACR-368, evaluated as a single agent in endometrial cancer subjects identified as OncoSignature-positive, demonstrated an objective response rate <a href=\"https://laohu8.com/S/ORR\">$(ORR)$</a> of 39% in the analyzed cohort. The company's AI-driven AP3 platform, designed to match disease-driving pathways with drug mechanisms, was also highlighted as a key component of its approach to precision medicine. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acrivon Therapeutics Inc. published the original content used to generate this news brief on January 08, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ACRV","symbol_name":"Acrivon Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL19znTz:1","article_id":"2602326275","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602326275","pubTimestamp":1767950092,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Acrivon Therapeutics Inc. recently held a conference call to discuss clinical data and pipeline updates for its leading drug candidates, ACR-368 and ACR-2316. The presentation included initial Phase 1 clinical data for ACR-2316 and Phase 2b data for ACR-368, with updates on program progress and the nomination of a development candidate for the company’s cell cycle program. ACR-368, evaluated as a single agent in endometrial cancer subjects identified as OncoSignature-positive, demonstrated an objective response rate  of 39% in the analyzed cohort. The company's AI-driven AP3 platform, designed to match disease-driving pathways with drug mechanisms, was also highlighted as a key component of its approach to precision medicine. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ACRV":"Acrivon Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Acrivon Therapeutics公布ACR-368和ACR-2316的临床数据和管线更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACRV":0.9},"content_text":"Acrivon Therapeutics Unveils Clinical Data and Pipeline Updates for ACR-368 and ACR-2316\n    \n\n        Acrivon Therapeutics Inc. recently held a conference call to discuss clinical data and pipeline updates for its leading drug candidates, ACR-368 and ACR-2316. The presentation included initial Phase 1 clinical data for ACR-2316 and Phase 2b data for ACR-368, with updates on program progress and the nomination of a development candidate for the company’s cell cycle program. ACR-368, evaluated as a single agent in endometrial cancer subjects identified as OncoSignature-positive, demonstrated an objective response rate $(ORR)$ of 39% in the analyzed cohort. The company's AI-driven AP3 platform, designed to match disease-driving pathways with drug mechanisms, was also highlighted as a key component of its approach to precision medicine. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acrivon Therapeutics Inc. published the original content used to generate this news brief on January 08, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}